EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the mechanism of epigallocatechin-3-gallate on ovarian cancer based on network pharmacology and experimental validation

Yufeng Cai, Xiaoyan Liu, Yang Wang, Ting Liu, Zhu Yi, Qingrui Wang

Letters in Drug Design & Discovery · 2026-09 · 23 (9) · 100599

DOI: 10.1016/j.lddd.2026.100599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-09. Verfasst von Yufeng Cai und 5 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian cancer is associated with a poor prognosis, largely due to late-stage diagnosis and the development of therapy resistance. The green tea polyphenol epigallocatechin-3-gallate (EGCG) shows anti-tumor potential, but its targets and mechanisms in ovarian cancer remain unclear. This study aims to identify the key molecular targets and elucidate the underlying mechanisms of EGCG’s action in ovarian cancer.

Methods

Differentially expressed genes (DEGs) in the GSE18520 dataset were identified using the limma package (|log 2 fold change| > 2, adjusted p 0.8, |Gene Significance| > 0.2), and EGCG targets from the Comparative Toxicogenomics. Three machine learning algorithms, including least absolute shrinkage and selection operator (LASSO) (5-fold cross-validation), support vector machines-recursive feature elimination (SVM-RFE), and random forest (RF) (Gini index), were applied to identify core targets. Cells were randomly assigned to Control, EGCG-treated, and EGCG + potassium voltage-gated channel subfamily H member 2 (KCNH2)-overexpression groups. In vitro experiments (Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry) and molecular docking (AutoDock Vina) were used for validation.

Results

A total of 1204 DEGs were identified (|log 2 fold change| > 2, adjusted p < 0.05). WGCNA identified 8 co-expression modules, among which the brown module (containing 386 genes) showed the strongest correlation with ovarian cancer. Intersection analysis yielded 19 common genes, and machine learning further narrowed this to KCNH2 as the sole overlapping target. KCNH2 was up-regulated in ovarian cancer tissues and cell lines ( p < 0.01). Molecular docking predicted a potentially favorable interaction between EGCG and KCNH2, with a binding energy of −6.7 kcal/mol. Functionally, EGCG inhibited ovarian cancer cell viability ( p < 0.01), and KCNH2 overexpression reversed EGCG-induced decrease in KCNH2 expression ( p < 0.05). Additionally, EGCG reduced colony formation and induced apoptosis ( p < 0.001), while KCNH2 overexpression reversed these effects ( p < 0.01).

Conclusion

Based on bioinformatic and in vitro analyses, EGCG appears to suppress ovarian cancer cell growth and promote apoptosis partly by targeting and down-regulating KCNH2. These preliminary findings propose the EGCG-KCNH2 axis as a candidate mechanism warranting further preclinical investigation. However, given that the current evidence is limited to computational predictions and cell-based assays, additional studies in animal models and clinical specimens are necessary before any therapeutic implications can be considered. Nevertheless, this work provides a testable mechanistic hypothesis for EGCG’s anti-ovarian cancer activity, distinguishing it from non-specific anti-proliferative effects.

Zitieren

APA

Cai, Y., Liu, X., Wang, Y., Liu, T., Yi, Z., & Wang, Q. (2026). Exploring the mechanism of epigallocatechin-3-gallate on ovarian cancer based on network pharmacology and experimental validation. Letters in Drug Design & Discovery, 23(9), 100599. https://doi.org/10.1016/j.lddd.2026.100599

Vancouver

Cai Y, Liu X, Wang Y, Liu T, Yi Z, Wang Q. Exploring the mechanism of epigallocatechin-3-gallate on ovarian cancer based on network pharmacology and experimental validation. Letters in Drug Design & Discovery. 2026;23(9):100599. doi:10.1016/j.lddd.2026.100599

BibTeX
@article{Cai2026,
  author = {Cai, Yufeng and Liu, Xiaoyan and Wang, Yang and Liu, Ting and Yi, Zhu and Wang, Qingrui},
  title = {Exploring the mechanism of epigallocatechin-3-gallate on ovarian cancer based on network pharmacology and experimental validation},
  journal = {Letters in Drug Design & Discovery},
  year = {2026},
  volume = {23},
  number = {9},
  pages = {100599},
  doi = {10.1016/j.lddd.2026.100599}
}
Kostenlos starten →